Drug Profile
Research programme: cancer therapeutics - BioLineRx
Alternative Names: BL-2010; BL-2030; BL-3040; BL-4050; BL-5020; BL-M010; EDP 08; EDP 17; EDP 19; EDP 20; EDP 23; EDP 24; EDP-33Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator BioLineRx
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in Israel
- 08 Jan 2013 Early research is ongoing in Israel
- 19 Mar 2009 Early research is ongoing in Israel